ESG

Agamon Health's new OncoPrep tool uses 'agentic AI' to automate complex pre-visit tasks, promising faster, more coordinated cancer care.

As Washington seeks mineral independence, a new venture in the DRC aims to supply tungsten, a vital metal for tech and defense, from under China's shadow.

The brand's dual Parents Magazine awards highlight its leadership in safety, meeting new CPSC rules and catering to the modern, eco-conscious parent.

A landmark study reveals 100% tumor control with a personalized radiation therapy, offering profound new hope for patients with inoperable liver cancer.

A landmark deal brings advanced hydrogen storage and refueling tech to Vietnam, accelerating the nation's green energy strategy through regional collaboration.

As women in midlife turn to drugs like Ozempic, a new crisis is emerging: significant muscle loss. A new approach aims to protect metabolic health.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

CHC: Creating Healthier Communities adds policy expert Edo Banach to its board, a strategic move to leverage his deep Medicare and Medicaid expertise.

Israel's parliament passes a major R&D tax overhaul, offering huge credits to counter global tax reforms and secure its 'Startup Nation' status.

With deep D.C. experience, Scott Dziengelski takes the helm at NABH, poised to tackle pressing issues like parity, workforce, and the addiction crisis.

A landmark deal aims to turn a manufacturing hub into a design capital, but can Guangzhou overcome the challenges of its rapid transformation?

A new transatlantic fund aims to bridge the biodiversity funding gap by investing in regenerative farms and forests, betting that healing nature can also yield profit.

Ditching the old OEM model for a 'win-win ecosystem,' Chery bets on shared tech and green manufacturing. A global summit will test this bold new vision.

Italian infrastructure giant Mundys can now own nearly 30% of Getlink, a key move in European transport that passed the UK's strict security review.

IVY Rx unveils its 2026 compounded GLP-1 program with clear pricing, but operates in a market facing intense FDA warnings and regulatory uncertainty.

The market for at-home NAD+ therapy is booming, but as telehealth offers new convenience, it faces a wave of regulatory and safety questions.

Replimune halts a promising cancer therapy and cuts jobs after a stunning FDA rejection, citing a 'failed' system and inconsistent regulatory process.

Diamondback Energy is buying back nearly $1 billion in long-term debt. What does this strategic financial move reveal about its future and the energy sector?

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.

Gensler's Andy Cohen joins the REIT's board, signaling a strategic shift toward design-led development in LA and Honolulu's premium real estate markets.